Poland· PL-100522225
Aucatzyl
A antineoplastic cell and gene therapy product containing obecabtagene autoleucel, registered in Poland by Autolus GmbH. The same ATC class is registered in 2 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Obecabtagene autoleucel is registered in 2 of 19 countries.
Countries holding a registration under ATC L01XL (antineoplastic cell and gene therapy), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 1 of them publish a price we can compare per daily dose
Obecabtagene autoleucel · ATC L01XL
2 / 19 countries
- Denmark
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- obecabtagene autoleucel
- Manufacturer
- Autolus GmbH
- Country
- Poland (PL)
- ATC code
- L01XL
- ATC class
- Antineoplastic cell and gene therapy
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Obecabtagene autoleucel in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumAucatzyl 410 10*6 cellsAutolus
- CzechiaAUCATZYLAutolus GmbH, Weil am Rhein
- FinlandAucatzylAutolus GmbH
- United KingdomAucatzyl 410million cells dispersion for infusion bagsAutolus Ltd
- IrelandAucatzyl 410 × 106 cells dispersion for infusionAutolus GmbH
- IcelandAucatzylAutolus GmbH
- NetherlandsAucatzyl 410 × 106 cellen dispersie voor infusieAutolus GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Aucatzyl
- Liechtenstein · Aucatzyl
- Norway · Aucatzyl
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a6012f71-ea53-4a0a-94b9-d0dd85322a74 GET /v1/drugs/a6012f71-ea53-4a0a-94b9-d0dd85322a74?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Dyspersja do infuzji",
"source": "urpl",
"strength": "410 × 106 komórek",
"packaging": "Rpz ¦ EU/1/25/1951/001 ¦ 163115\n1 opak.",
"substance": "Obecabtagene autoleucel 410 × 106 komórek",
"common_name": "obecabtagene autoleucel",
"pl_product_id": "100522225",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about obecabtagene autoleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.